Business Wire

Valbiotis Consolidates Its Development of Innovative Natural Health Solutions by Integrating the Exploration of Microalgae Produced in New Caledonia, Through an Exclusive Agreement With ADECAL-Technopole and IFREMER

Share

Regulatory News:

Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible), a French research and development company committed to scientific innovation for preventing and combating of metabolic diseases, announces the consolidation of its development of innovative natural health solutions, by integrating the exploration of microalgae produced in New Caledonia, through an exclusive agreement with ADECAL-Technopole and IFREMER. This program should allow to develop a bank of high-potential strains selected by ADECAL-Technopole and IFREMER since 2013 in New Caledonia as part of the "AMICAL" joint research project.

Valbiotis will carry out the work necessary to demonstrate the health benefits of these microalgae strains at its preclinical platform in Riom, with a view to filing new patents. Once this scientific validation has been achieved, production will be ensured in New Caledonia for the industrial scale-up, thanks to existing and operational pilot infrastructure for which the technology and know-how will be transferred to private operators. For their marketing, these new health solutions will need to obtain "GRAS" regulatory status in the United States and "Novel Food" status in Europe. They may be incorporated into foodstuffs, presented in the form of food supplements or formulated as medical nutrition.

The tripartite agreement with ADECAL-Technopole and IFREMER provides for exclusive commercial exploitation rights of these microalgae for Valbiotis1. The microalgae market will grow at an annual rate of 3.5% to reach $3.8 billion by 20242.

Sébastien PELTIER, CEO, Chairman of the Board of Directors of Valbiotis, comments: "This is a Research & Development program that has been close to my heart for many years and that I am delighted to be able to implement today with ADECAL-Technopole and IFREMER. The use of plant resources, both terrestrial and marine, can provide a solution to tomorrow's health needs. This growing market benefits from the strong worldwide demand for innovative, natural and effective molecules for health. Since the identification and combination of active plant substances is central to our expertise, it makes perfect sense to extend our know-how to marine biotechnologies and microalgae, the beneficial properties of which should lead to the filing of new patents. In addition, contributing to the development of an innovative microalgae production sector in New Caledonia, participating in local economic growth and enhancing the biodiversity of the lagoon in the long term are important sustainable development objectives for Valbiotis."

Adrien RIVATON, Managing Director of ADECAL-Technopole, explains:"We have developed a marine cluster in order to contribute to the development of the blue economy and more specifically to promote the development of the aquaculture and marine biotechnology sectors, based on the richness of local marine ecosystems, whose potential for valorization is still largely under-exploited. The research collaboration with Valbiotis opens up new opportunities for experimentation on microalgae and promising prospects for our territory."

Romain CHARRAUDEAU, Director of Partnership and Innovation Transfer at IFREMER adds: "IFREMER is a place where knowledge and skills in research, technology and innovation concerning the marine environment are brought together. It plays an inspiring and galvanizing role, ensuring the engagement of scientific communities through partnership approaches that involve public & private actors in the development and implementation of research programs. The research collaboration with Valbiotis has been concluded within the framework of this strategy."

Valbiotis, ADECAL-Technopole and IFREMER are committed to respecting the three pillars of the Nagoya Protocol which came into force on October 12, 2014 and stems from the Convention on Biological Diversity. As such, they are committed to carrying out their research and development activities in accordance with the applicable ABS3 regulations and to ensuring traceability with the competent authorities before the implementation of any research program requiring the use of biological material.

Microalgae: a resource of the future for human food and health

These marine plant organisms, more commonly known as "phytoplankton", are about a micrometer in size and constitute a remarkable source of biodiversity, still largely unexplored, and an abundant resource that can be exploited by marine biotechnologies.

These fast-growing microorganisms use light to generate a biomass rich in proteins, lipids and sugars, bioactive compounds (polyphenols, tocopherols, ascorbic acid) and pigments (chlorophyll, carotenoids, phycobilins)4,5. The diversity of these molecules of interest and their ease of production offer tremendous potential for innovation in the nutrition and health sectors, but also in energy, chemistry and cosmetics, with industrial applications already available4,5. In the health field, microalgae have, for example, antibacterial, antifungal, anti-free radical, anti-inflammatory and anti-tumor properties5.

The microalgae market will grow at an annual rate of 3.5% to reach $3.8 billion by 20242.

AMICAL: a microalgae development program, launched in 2013 by Adecal-Technopole and IFREMER in New Caledonia

Resulting from a collaboration and co-ownership agreement between the LEAD unit of IFREMER (Lagoons, Ecosystems and Sustainable Aquaculture in New Caledonia) and ADECAL-Technopole, the joint research program "AMICAL" aims to develop an innovative microalgae production chain in New Caledonia and to valorize the results of research in this field. It has received funding from New Caledonia, the three Provinces and the French State.

Since 2013, the Laboratoire d'Étude des Micro-Algues (LEMA) and the Laboratoire Technologique des Micro-Algues (LTMA) have conducted their bioprospecting operations in New Caledonian coastal waters to select species with high growth potential and build a strain library of New Caledonian microalgae of interest.

The research has mainly focused on the biochemical characterization of the selected microalgae: energy content, proteins and amino acids, lipids and fatty acids, sugars and natural bioactive substances with high added value for applications in nutrition and health. This strain selection work paves the way for preclinical experiments which Valbiotis will be responsible for under the tripartite agreement.

About IFREMER
IFREMER is a public body of an industrial and commercial nature. It contributes to the French research and innovation system, as well as to the European research area, through the production of fundamental knowledge via a systemic approach enabling a better understanding of the processes that govern ecosystems and the changes that affect them. IFREMER is also involved in economic development through numerous partnerships with industry and the economy, and the promotion of the Institute's innovations.

About ADECAL
ADECAL Technopole is an association under the French law of 1901, mainly financed by the French State, New Caledonia and its three provinces. It works to promote the competitiveness and attractiveness of New Caledonia through experimentation, transfer and innovation, and comprises four clusters (marine, land, agri-food and innovation) as well as technology centers. ADECAL Technopole contributes to the development of natural marine and terrestrial resources as well as to the emergence of innovative projects and sectors, in favor of sustainable development in order to diversify the New Caledonian economy.

About Valbiotis
Valbiotis is a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases in response to unmet medical needs.
Valbiotis has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of health nutrition products designed to reduce the risk of major metabolic diseases, based on a multi-target approach enabled by the use of plant-based terrestrial and marine resources.
Its products are intended to be licensed to players in the health sector.
Created at the beginning of 2014 in La Rochelle, the Company has forged numerous partnerships with leading academic centers. The Company has established three sites in France - Périgny, La Rochelle (17) and Riom (63) – and a subsidiary in Quebec City (Canada) .
Valbiotis is a member of the "BPI Excellence" network and has been recognized as an "Innovative Company" by the BPI label. Valbiotis has also been awarded "Young Innovative Company" status and has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). Valbiotis is a PEA-SME eligible company.
For more information about Valbiotis, please visit: www.valbiotis.com

Name: Valbiotis
ISIN code: FR0013254851
Ticker symbol: ALVAL
EnterNext© PEA-PME 150

This press release contains forward-looking statements about Valbiotis’ objectives. Valbiotis considers that these projections are based on rational hypotheses and the information available to Valbiotis at the present time. However, in no way does this constitute a guarantee of future performance, and these projections may be affected by changes in economic conditions and financial markets, as well as certain risks and uncertainties, including those described in the Valbiotis Universal Registration Document approved by the French Financial Markets Regulator (AMF) on July 27, 2021 (application number R 21-039). This document is available on the Company’s website (www.valbiotis.com).
This press release and the information it contains do not constitute an offer to sell or subscribe, or a solicitation to purchase or subscribe to Valbiotis’ shares or financial securities in any country.


1The field of operation is defined as follows: "Nutraceuticals, drugs and medical devices in human and animal health in the strict context of the prevention and treatment of the following metabolic diseases: diabetes, dyslipidemia, hypertension, overweight, obesity, NAFLD (Non-alcoholic fatty liver disease)."
2Global Microalgae Market Growth 2019-2024, Fior Markets, 2019; https://www.fiormarkets.com/report/global-microalgae-market-growth-2019-2024-372987.html
3The regulation of access and benefit sharing from the use of genetic resources and associated traditional knowledge (ABS).
4Microalgae: behind the scenes of a revolution, Le Journal du CNRS, April 2019; https://lejournal.cnrs.fr/diaporamas/microalgues-les-coulisses-dune-revolution
5Microalgae Aquaculture in New Caledonia (AMICAL), IFREMER, June 2016; https://nouvelle-caledonie.ifremer.fr/Biodiversite-et-ressources/Aquaculture-de-micro-algues

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Corporate communication / Valbiotis
Carole ROCHER / Marc DELAUNAY
+33 5 46 28 62 58
media@valbiotis.com

Financial communication / Actifin
Stéphane RUIZ
+33 1 56 88 11 14
sruiz@actifin.fr

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

H.I.G. Capital Announces the Sale of DGS S.p.A.11.6.2024 12:00:00 CEST | Press release

H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with $62 billion of capital under management, is pleased to announce that an affiliate has signed a definitive agreement to sell its portfolio company, DGS S.p.A. (“DGS” or the “Group”), a leading firm in the Italian Information Technology market, to DGS Co-Founders and management team in partnership with ICG, a global alternative asset manager. Since its inception in 1997, DGShas supported blue-chip customers in the design, integration, and maintenance of complex IT systems, with a specialization in digital transformation and cybersecurity services. The Group currently has over 1,900 employees, revenues of approximately €300 million, and maintains a group of highly loyal clientele. During H.I.G.’s ownership, DGS has tripled in size and consolidated its position as a leading Italian firm in cybersecurity services and digital transformation. DGS offers its clients sophisticated and proprietary digital transformation

Evertas Names Nick Selby Head of European Underwriting11.6.2024 12:00:00 CEST | Press release

Evertas, the world’s first crypto insurance company, has named Nick Selby as its new Head of European Underwriting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611141887/en/ Nick Selby, Executive Vice President and Head of European Underwriting at Evertas (Photo: Business Wire) Selby, an accomplished information and physical security professional, brings two decades of expertise in public and private sector information security, physical security, and complex incident handling, as well as seven years of experience leading teams securing billions of dollars in cryptoassets. Previously, his roles included VP of the Software Assurance Practice at Trail of Bits, Chief Security Officer at Paxos Trust Company, and Director of Cyber Intelligence and Investigations at the NYPD Intelligence Bureau. “Nick is an extremely valuable addition to our European team,” said Evertas CEO and Co-Founder J. Gdanski. “His public and private

Owlet utvider globalt fotavtrykk med lanseringen av medisinsk-sertifisert Dream Sock™ i Storbritannia og over hele Europa11.6.2024 11:00:00 CEST | Pressemelding

Owlet, Inc. («Owlet» or the «Company») (NYSE:OWLT), pioneren innen smart spedbarnsovervåking, kunngjør i dag den britiske og europeiske lanseringen av Dream Sock. Dette er en smart babymonitor med levende helseavlesninger og varsler for friske spedbarn mellom 0-18 måneder og 2,5-13,6 kg. Dette innovative medisinske utstyret gir foreldre helse og viktig informasjon i sanntid, noe som gir uovertruffen trygghet. Denne pressemeldingen inneholder multimedia. Se hele pressemeldingen her: https://www.businesswire.com/news/home/20240611820341/no/ (Photo: Business Wire) «Vi er svært stolte over å lansere Dream Sock til omsorgspersoner over hele Storbritannia og Europa og gi millioner av foreldre mer trygghet mens babyen sover,» sa Kurt Workman, Owlets administrerende direktør og medgründer. «Dream Sock er nå et globalt produkt som er anerkjent som medisinsk nøyaktig og trygt, etter å ha gjennomgått regulatoriske autorisasjoner og sertifiseringer innenfor flere geografier. I dag er misjonen vår

V-Nova Surpasses 1000 Patent Milestone in Media Technology Innovation11.6.2024 10:00:00 CEST | Press release

V-Nova, a leading provider of data compression solutions, video compression technology, XR technology, AI acceleration and parallel processing for a multitude of industries including media and entertainment, today announced its milestone achievement of 1000 active technology patents. This accomplishment underscores V-Nova’s dedication to research and development and its commitment to protecting its intellectual property globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611724561/en/ V-Nova’s patent portfolio spans more than 50 different jurisdictions. Including over 400 patents in Europe, over 200 in the Americas, over 100 in the United States specifically, and over 200 in Asia. V-Nova forged new directions in data processing to enhance digital experiences, maximize efficiency, reduce costs, and increase sustainability. The company leads the way with key international data compression standards for the video indust

Alipay+ Reveals Top Scorer Trophy Design for UEFA EURO 2024™11.6.2024 09:24:00 CEST | Press release

Alipay+, a suite of cross-border mobile payment and digitalization technology solutions operated by Ant International and an Official Partner of UEFA EURO 2024™, today revealed the trophy that will be awarded to the most prolific marksman at the UEFA EURO 2024™ finale on July 14 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240610328619/en/ The UEFA Top Scorer Trophy presented by Alipay+ is unveiled for UEFA EURO 2024™ (Photo: Business Wire) Sculpted in the shape of the Chinese character “支” (pronounced zhi, and meaning payment as well as support), the trophy reflects Alipay+’s dedication to supporting consumers to enjoy seamless payment and a broad choice of deals using their preferred payment methods while traveling abroad. The character also resembles the fleeting moment of a barefooted striker poised to shoot, evoking the original beauty and power of football – a game that united people across the wo

World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye